Cell therapy developer Be Bio hauls in $130M for pipeline in rare disease, cancer
Be Biopharma is developing cell therapies by engineering B cells to churn out therapeutic proteins with an initial focus on cancer and rare disease. The […]
Be Biopharma is developing cell therapies by engineering B cells to churn out therapeutic proteins with an initial focus on cancer and rare disease. The […]
ARCH Venture Partners led the Series C round of financing for Nutcracker Therapeutics, a company developing new RNA drugs. The company’s process for developing and […]
Neumora Therapeutics unveiled $500 million in capital and a research partnership with Amgen. The startup analyzes neurological data to inform its drug research and development; […]
Kris Engskov — an official in the Bill Clinton White House, a long-time executive with Starbucks and most recently president of senior living provider Aegis […]
Interline Therapeutics has technology that shows how proteins interact as communities, paving the way for the discovery of new drugs. CEO Zachary Sweeney, a Denali […]
“Everybody’s an infectious disease company now,” ARCH Venture Partners Managing Director Bob Nelsen said. By contrast, a report last year showed a huge decline in […]
The company is developing biosensors, initially for NASH, that could be used in place of liver biopsy and have applicability in development of drugs for […]
Copyright © 2024 | WordPress Theme by MH Themes